Khalid El Bairi: The accessibility and affordability of global oncology conferences for young oncologists from LMICs
Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared on X about recent paper by him as first author, titled “Diversity and Inclusivity Considerations Are Key When Choosing a Global Oncology Conference Location” published on JCO Global Oncology.
Authors: Khalid El Bairi, Abigiya Wondimagegnehu, Shah Zeb Khan, Dario Trapani, and Omar Abdihamid
“Excited to share our new paper in JCO Global Oncology! It highlights critical issues surrounding the accessibility and affordability of global oncology conferences for young oncologists and researchers from LMICs.”
Khalid El Bairi, founder of The Cancer Biomarkers Working Group, specializes in clinical and translational research in medical oncology. With many peer-reviewed articles, he delves into predictive and prognostic cancer biomarkers, especially for digestive and gynecological cancers like ovarian and colorectal malignancies. El Bairi holds board positions in international scientific societies such as IGCS, ESMO, ASCO, ESGO, and AACR. Serving as editor and reviewer for over 40 journals, he also educates medical and Ph.D. students on evidence-based medicine, research methodologies, and publishing ethics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023